Literature DB >> 17585312

Intravitreal triamcinolone and bevacizumab combination therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone.

N S Ekdawi, S J Bakri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17585312     DOI： 10.1038/sj.eye.6702903

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  3 in total

1.  Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up.

Authors:  Rita Ehrlich; Thomas A Ciulla; Adam M Moss; Alon Harris
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-11-08       Impact factor: 3.117

2.  Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab.

Authors:  Seul Gi Yoo; Jae Hui Kim; Tae Gon Lee; Chul Gu Kim; Jong Woo Kim
Journal:  Indian J Ophthalmol       Date:  2015-01       Impact factor: 1.848

3.  Comparison of treatment response to intravitreal injection of triamcinolone, bevacizumab and combined form in patients with central retinal vein occlusion: A randomized clinical trial.

Authors:  Ghader Motarjemizadeh; Miaad Rajabzadeh; Naser Samadi Aidenloo; Rohollah Valizadeh
Journal:  Electron Physician       Date:  2017-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.